Trial Profile
A Multicenter Phase II trial of TS-1/oxaliplatin (SOX) +bevacizumab in patients with unresectable advanced/metastatic colorectal cancer (HiSCO-02).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 May 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 22 Apr 2011 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
- 08 Mar 2011 New trial record